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Abstract
This paper presents the rationale, design, and methods of the Pediatric Obsessive-Compulsive
Disorder Treatment Study II (POTS II), which investigates two different cognitive-behavior therapy
(CBT) augmentation approaches in children and adolescents who have experienced a partial
response to pharmacotherapy with a serotonin reuptake inhibitor for OCD. The two CBT
approaches test a "single doctor" versus "dual doctor" model of service delivery. A specific goal was
to develop and test an easily disseminated protocol whereby child psychiatrists would provide
instructions in core CBT procedures recommended for pediatric OCD (e.g., hierarchy
development, in vivo exposure homework) during routine medical management of OCD (I-CBT).
The conventional "dual doctor" CBT protocol consists of 14 visits over 12 weeks involving: (1)
psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure with response
prevention (EX/RP). I-CBT is a 7-session version of CBT that does not include imaginal exposure
or therapist-assisted EX/RP. In this study, we compared 12 weeks of medication management (MM)
provided by a study psychiatrist (MM only) with two types of CBT augmentation: (1) the dual
doctor model (MM+CBT); and (2) the single doctor model (MM+I-CBT). The design balanced
elements of an efficacy study (e.g., random assignment, independent ratings) with effectiveness
research aims (e.g., differences in specific SRI medications, dosages, treatment providers). The
study is wrapping up recruitment of 140 youth ages 7–17 with a primary diagnosis of OCD.
Independent evaluators (IEs) rated participants at weeks 0,4,8, and 12 during acute treatment and
at 3,6, and 12 month follow-up visits.
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Introduction
The Pediatric Obsessive-Compulsive Disorder Treatment
Study Part II (POTS II) evolved out of a collaborative rela-
tionship among investigators at the University of Pennsyl-
vania (Drs. Edna Foa & Martin Franklin), Duke University
(Dr. John March), and Brown University (Drs. Henrietta
Leonard & Jennifer Freeman) and their respective research
teams that began years earlier with the Pediatric Obses-
sive-Compulsive Disorder Treatment Study (POTS I). The
POTS I project was the first randomized trial in pediatric
obsessive-compulsive disorder (OCD) to compare
directly the efficacy of an established medication (sertra-
line), OCD-specific cognitive behavioral treatment (CBT),
and their combination, to a placebo control condition in
the initial treatment of children and adolescents with clin-
ically significant OCD [1,2].
The ideal initial treatment for OCD in youth is CBT alone
or CBT in combination with a serotonin reuptake inhibi-
tor (SRI) [2-4]. However, despite expert recommenda-
tions to start with CBT or CBT plus an SRI,
pharmacotherapy with an SRI alone is a widely used ini-
tial treatment for OCD in patients of all ages [5,6]. In
addition, most patients who receive pharmacotherapy
evidence a partial response, with clinically significant
residual symptoms [2].
POTS II was designed to investigate two different CBT aug-
mentation protocols in children and adolescents with a
diagnosis of OCD who are partial responders to defined
adequate SRI pharmacotherapy. Specifically, POTS II is a
balanced 3 (site) × 3 (treatment conditions) × 4 (repeated
measures) masked randomized parallel group controlled
trial that compares 12 weeks of medication management
(MM) provided by a study psychiatrist with two types of
CBT augmentation: (1) MM + OCD-specific CBT as deliv-
ered by a study psychologist (MM+CBT); and (2) MM +
instructions in CBT (MM+I-CBT) delivered by the same
study psychiatrist who provides MM. The design has ele-
ments of an efficacy study (e.g., random assignment, inde-
pendent ratings, checks on treatment fidelity), but the
primary aim of the study was not to test the relative differ-
ence between two different psychotherapy approaches,
but rather how to implement CBT for pediatric OCD in a
format that can be available to the most possible patients.
We hypothesized that a two-doctor model including a
highly-trained CBT therapist for OCD would be more effi-
cacious, but perhaps more expensive or otherwise una-
vailable to many people suffering from OCD. The MM+I-
CBT approach, if shown to be comparable overall or with
some subset of the patients treated, could be a means
where community psychiatrists could be trained in an
approach that is efficacious for pediatric OCD, but still
feasible within a community practice. While differences
between MM+CBT and MM+I-CBT cannot be attributable
to the specific treatment components of one treatment
versus another (e.g., in-session exposure with response
prevention (EX/RP)), our design will allow us to estimate
the effect size associated with each specific treatment in a
"real world" population of youth with OCD. Addition-
ally, the design allows for an examination of the feasibility
of the I-CBT approach (i.e., does this treatment work at
all? Do patients attend? Can physicians do CBT in this
context?). Finally, the data from this study will begin to
answer questions about which treatments may work best
for whom (e.g., do those youth with OCD who are more
ill require MM+CBT while those who are not as ill may do
fine with the less intensive treatment?). This report
presents the rationale for the study, describes the design
choices made, and outlines the methods used to carry out
the trial.
Background for POTS II
Obsessive Compulsive Disorder (OCD) is a serious and
significant psychiatric disorder in early childhood, affect-
ing between 0.5% [7] and 2–3% of children [8,9]. Among
adults with OCD, 1/3 to 1/2 develop the disorder in child-
hood or adolescence [10]. OCD severely impairs aca-
demic, social and family functioning [11-14]. Thus,
effectively treating OCD in young people may improve
functioning and reduce lifelong morbidity, resulting in
significant public health benefit.
Evidence-based Treatment of Pediatric OCD
Evidence for SRIs
With respect to SRI treatment of OCD, the pediatric liter-
ature is consistent with the adult trials in revealing: (1) lit-
tle placebo effect; (2) a 30–40% reduction in OCD
symptoms, which corresponds to an average 6 point
decrease on the Child Yale-Brown Obsessive Compulsive
Scale (CY-BOCS); and (3) clinical effects beginning at
three weeks, reaching a plateau at after ten weeks [15].
Notably, the majority of patients are left with residual
symptoms even after an adequate course of treatment
with SRI medication [2].
Experts recommend combining CBT or, less preferably in
light of their relative side effect profiles, an atypical neu-
roleptic to SRI treatment in partial responders [3,4]. To
date, no controlled studies have evaluated the efficacy of
augmentation treatment in pediatric OCD, which leaves
the field without an adequate scientific foundation to
guide the management of partial response.
Evidence for CBT
Expert clinical panels have long recommended starting
with CBT or CBT plus an SRI as the treatment of choice for
OCD in youth [3,4], but it is only recently that practice
guidelines have been supported by the evidence baseChild and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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[2,16]. The CBT outcome literature in pediatric OCD
began with age-downward extension of protocols found
efficacious with adults, then publication of single case
studies, case series, and open trials involving these proto-
cols [17-20]. These uncontrolled evaluations yielded
remarkably similar and encouraging findings across set-
tings and cultures: at post-treatment, the vast majority of
patients were responders, with mean CY-BOCS reductions
ranging from 50% – 67%. This pilot work set the stage for
controlled studies evaluating the efficacy of CBT, one of
which was published in the late 1990s [21], four that have
been published more recently [2,22-24], and one that has
recently been completed (J. Piacentini, personal commu-
nication).
Most of the studies of CBT outcome in pediatric OCD
have employed similar protocols involving weekly treat-
ment over 12–14 weeks (see references above). In con-
trast, Weaver and Rey used an intensive CBT protocol that
included two information gathering sessions followed by
10 daily sessions of CBT over 2 weeks [20]. Franklin et al.
found no differences between 14 weekly sessions over 12
weeks or 18 sessions over 4 weeks, but interpretation of
this finding is hampered by the lack of random assign-
ment [17]; a similar but larger study in adults found no
difference at follow-up between intensive and twice-
weekly CBT [25]. Storch et al. randomized pediatric OCD
patients to receive either intensive or weekly CBT and
found that patients respond well to CBT delivered either
weekly or intensively [23].
The three pediatric CBT pilot studies that have included a
follow-up evaluation support the durability of CBT, with
therapeutic gains maintained up to 9 months post-treat-
ment [17,18,20]. Moreover, since relapse commonly fol-
lows medication discontinuation, the finding of March et
al. that improvement persisted in six of nine responders
following the withdrawal of medication provides limited
support for the hypothesis that CBT inhibits relapse when
medications are discontinued [18]. Follow-up data from
Barrett et al.'s study further indicate the durability of gains
made in CBT for pediatric OCD [26].
A recent meta-analysis of CBT for OCD in pediatric
patients found that CBT generally outperformed SRIs
alone providing further support to the evidence base for
CBT [16]. However, further subanalyses of the data sug-
gest that this finding was confounded because many of
the open CBT treatment studies included in the meta-
analysis included patients receiving a serotonin reuptake
inhibitor (SRI) in conjunction with their CBT treatment
[27,28]. Only 4 or 18 CBT studies examined the efficacy of
CBT in children on no medication [27]. The literature sug-
gests that a majority of children presenting for CBT treat-
ment for OCD are already receiving stable SRI treatment,
indicating a need to clarify the augmenting role of CBT in
treatment of OCD.
Evidence for combined treatment
POTS I is the only study that has directly compared com-
bined treatment with CBT and SRI pharmacotherapy in a
randomized controlled trial. POTS I's findings on the pri-
mary continuous outcome measure, the CY-BOCS [29],
indicated a statistically significant advantage for CBT
alone, sertraline alone, and combined CBT-sertraline
treatment relative to placebo. In addition, children receiv-
ing combined treatment had a larger reduction in OCD
symptoms than CBT or sertraline alone, which did not dif-
fer from each other [2]. Rates of clinical remission were:
Combined treatment (53.6%; 95% CI 36–70%), CBT
(39.3%; 95% CI 24–58), sertraline (21.4%; 95% CI 10–
40) and placebo (3.6%; 95% CI 0 – 19). Combined treat-
ment did not differ from CBT (p = .42), but did differ from
sertraline (p = .026) and from placebo (p < .001). CBT did
not differ from sertraline (p = .24), but did differ from pla-
cebo (p = .002), whereas sertraline did not (p = .10). The
authors concluded that children and adolescents with
obsessive-compulsive disorder should begin treatment
with the combination of CBT plus an SRI or CBT alone.
The results of the first POTS study also suggest that deliv-
ery of concomitant CBT can help reduce SRI doses. The
median dose of SSRI for children receiving combination
treatment was 150 mg, as compared to 200 mg for chil-
dren receiving sertraline alone or placebo [2]. However,
SRI partial responders may constitute a different and per-
haps more treatment non-responsive sample than those
who have participated in studies of initial treatments. If
there were evidence that CBT augmentation is effective
then further testing about its utility in pharmacotherapy
reduction and discontinuation could be pursued in future
studies.
Augmentation of medication
In adults, SRI treatment of OCD has generally been aug-
mented with antipsychotic medications, which cause a
significant risk for adverse events [30]. More recently, data
have emerged in support of CBT augmentation of SRI
treatment in adult OCD [31]. Simpson and colleagues
found that 8 weeks of CBT augmentation (17 sessions)
was superior to 8 weeks (17 sessions) of augmentation
with stress management training, but that 17 sessions of
CBT was not enough for most patients to achieve an excel-
lent response. They found that their study participants did
not do as well as participants in other studies who
received 15 sessions of OCD treatment daily prior to SRI
exposure [31].
While these data were not available during the study
design phase, in treatment of pediatric OCD, the empiri-Child and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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cally supported protocol is 14 sessions over 12 weeks [2]
and community treatments average approximately 10 ses-
sions [32]. Thus, the decision in the current study was to
follow the session timeline found to be efficacious in pre-
vious studies of childhood OCD. However, similar results
may develop in which children receiving an adequate SRI
treatment do not respond as well as children in previous
OCD treatment studies. In pediatric OCD, there are no
published augmentation trials, nor do we know of any in
progress. Three published open studies in the child and
adolescent literature suggest incremental benefit when
CBT is added to SRI pharmacotherapy in SRI partial
responders. One study reported a 50% CY-BOCS reduc-
tion following CBT in patients, 2/3rds of whom were par-
tially responsive to an SRI [18]. Similar results (59% CY-
BOCS reduction) [17,20] have been reported in youth
who were on a variety of SRIs when receiving CBT. Thus,
although CBT may be an efficacious augmentation treat-
ment in SRI partial responders, this has not been estab-
lished in a randomized controlled trial in this patient
population against an appropriate control condition. Spe-
cifically, there is little information in pediatric OCD about
whether CBT is as efficacious an augmentation agent as a
first line treatment.
Availability of CBT
Despite expert recommendation that CBT with a strong
emphasis on exposure with response prevention (EX/RP)
should be a first-line treatment for OCD in children and
adolescents [4], several barriers may limit its widespread
use. First, due to low base rates in the community as com-
pared with other anxiety disorders, few therapists have
extensive experience with CBT for pediatric OCD [7,33];
thus, CBT typically is available only in areas associated
with major medical centers if at all. In our clinical experi-
ence at three different anxiety disorders specialty clinics in
three diverse areas of the U.S., it is often difficult to find
clinicians in the community with specific expertise in CBT
for pediatric OCD. Again based on our experiences, those
clinicians who do have these skills often have considera-
bly long waiting lists. The scarcity of CBT practitioners is
by no means specific to pediatric OCD, but there are a
variety of possible explanations including: 1) insufficient
exposure during therapists' training to CBT in general and
more specifically CBT for OCD [34], 2) the typical psy-
chologist in clinical practice may not see a sufficient
number of pediatric OCD patients to develop expertise, 3)
resistance among therapists to adapt their preferred
approaches to accommodate newer techniques [34], and
4) an increasing focus on medication management
because of limited availability of CBT [35].
Second, even when the treatment is available, our experi-
ence has shown that some patients and families reject the
community based CBT treatment as "too difficult." Once
involved in CBT, some patients find the initial distress
when confronting feared thoughts and situations while
simultaneously refraining from rituals so aversive they
drop out of treatment. However, treatment drop out at
this stage may be due to insufficient skill on the part of the
clinician, as data from POTS I and other CBT for pediatric
OCD treatment studies have had fairly low drop out rates
[2], even when the treatment has been provided in the
community under the supervision of OCD experts [36].
Rationale For CBT in the context of medication 
management
Because of the difficulty in obtaining CBT for OCD in the
community, it is important to know whether instruction
in CBT procedures in the context of medication manage-
ment by the treating pharmacotherapist could be benefi-
cial for at least some children with residual OCD
symptoms despite being on medication. Such instruction
may enhance the typical partial response to SRI and be
easier to disseminate than the traditional dual doctor
model. In addition, instruction in CBT procedures may be
more feasible for clinicians operating in settings where in-
session therapist-assisted exposure may not be feasible.
A goal of POTS II was to develop an easily disseminated
protocol whereby child psychiatrists could instruct
patients in CBT procedures comparable to the recom-
mended CBT augmentation strategies. Additionally, by
testing a "one-doctor" (instructions in CBT in the context
of medication management) versus "two-doctor" (thera-
pist assisted CBT with psychologist in combination with
MM by child psychiatrist) model, it may be possible to
determine which pediatric OCD patients (i.e., those with
more severe illness, those with certain co-morbidities or
other external stressors, younger vs. older patients, etc...)
most benefit from a full course of more intensive CBT
which would allow for a more judicious use of limited
resources.
The POTS II study fills gaps in current pediatric OCD
research in the following ways: 1) POTS II has many
aspects of an effectiveness study. Children are not treat-
ment-naïve and this provides a very different sample from
one which examines initial treatment [2]. The inclusion
criteria also are broad, to promote generalizability to com-
munity practice. 2) POTSII is an augmentation study. All
children who entered the study were on a stable dose of an
SRI. A version of CBT was added to the treatment regimen,
to examine the incremental benefit of adding CBT for chil-
dren on a stable dose of medication. Because CBT exper-
tise in community settings is limited and because most
treated children and adolescents with OCD receive medi-
cations, it would be of substantial public health value to
know whether a practicable version of CBT that can be
delivered by child psychiatrists in the context of medica-Child and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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tion management can be successful in augmenting the
outcome by medication alone for children and adoles-
cents (with OCD) who are partial responders to an SRI. 3)
POTSII provides preliminary steps towards dissemina-
tion. This study will allow us to answer the question of
whether CBT can be adapted to be delivered in shorter and
fewer sessions, to allow for potential of increased access
and delivery by more providers in the context of other
treatment modalities, such as a medication management
visit. POTS II will also address the question of whether all
patients need therapist-assisted exposure or if some
patients improve with instructions alone, as a step toward
developing a stages of treatment model for pediatric
OCD.
Specific aims of POTS II
The collaborative R01 grant proposal was funded in 2003
by the National Institute of Mental Health. Following sev-
eral months of intensive training in study procedures,
patient enrollment began in 2004, with anticipated com-
pletion of recruitment in January 2009. The specific aims
are as follows:
Our primary specific aim for Phase I is:
1. To compare the short-term efficacy of MM+CBT and
MM+I-CBT to each other and to MM alone for OCD
symptoms and functional impairment for patients who
are partial responders to SRIs and seek augmentation
treatment.
Our primary specific aim for Phase II is:
2. To compare maintenance of gains monthly for six
months on OCD symptoms and functional impairment
for patients who responded to MM+CBT and MM+I-CBT
after both forms of treatment are discontinued.
Our secondary aim is:
3. To explore predictors of response (Phase I) and relapse
(Phase II), including demographics, age of onset, comor-
bid tics, insight, initial severity, comorbid internalizing
and externalizing symptoms, and family psychopathol-
ogy.
As explained in more detail in the introduction, the design
balanced elements of an efficacy study (e.g., random
assignment, independent ratings) with effectiveness
research aims (e.g., differences in specific SRI medica-
tions, dosages, treatment providers).
Methods of POTS II
The study is currently wrapping up recruitment of a volun-
teer sample of 140 youth age 7–17 with a diagnosis of
OCD based on criteria in the 4th edition of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV). All
children who participated in the study had by definition
experienced a partial response to SRI pharmacotherapy.
Children were randomly assigned to one of three possible
treatment conditions: (1) Medication Management (MM)
provided by a study psychiatrist; (2) OCD-specific CBT as
delivered by a study psychologist in addition to MM by a
study psychiatrist (MM+CBT); and (3) instructions in CBT
(MM+I-CBT) delivered by the study psychiatrist assigned
to provide MM.
Alternate design considerations
Although we believe that the experimental design we
selected provides a fair and ecologically valid test of two
distinct models for providing CBT augmentation to SRI
partial responders, several design alternatives and consid-
erations warrant elaboration:
Why Not Compare CBT Augmentation to Pharmacotherapy 
Augmentation?
Augmentation of SRIs with atypical neuroleptics such as
risperidone (RIS) is a clinical strategy supported by open
trials as well as by one randomized controlled trial, albeit
with adult OCD [37]. Although this is an important
research question, such a trial was unwarranted at the
time the current study was developed due to the lack of
evidence for the efficacy and safety of RIS augmentation
for children and adolescents.
Why Not Compare MM+CBT to I-CBT Conducted by a Psychologist?
Although the reduced visit schedule, contact time and
CBT component array that characterize MM+I-CBT
amount to a "low dose" version of CBT, the driving ration-
ale for MM+I-CBT is not primarily a test of low versus high
dose CBT but rather of a single versus a two doctor model
for administering CBT to SRI partial responders. Because
we intentionally crossed dose with provider in the MM+I-
CBT condition, we did not elect a third study arm in which
a low dose version of CBT was administered by a study
psychologist. First, the importance to the field of pursuing
multiple avenues in which to disseminate CBT ultimately
led us to choose the I-CBT program administered by the
psychiatrist. Second, given that we still needed to include
a control condition, adding this cell to the present design
would have reduced power to the point where examina-
tion of all of our study's primary aims would have been
severely compromised.
Why Not Do Double-Blinded SRI Discontinuation in Phase II?
We also considered and ultimately discarded the option
of re-randomizing MM+CBT responders to either con-
tinue or discontinue SRI. This design would have been a
direct test of the need for maintenance medication in CBT
augmentation responders. Although this is an interestingChild and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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and important question in and of itself, it was not possi-
ble within the constraints of time and budget. While this
type of approach has great appeal because it generates
knowledge about the optimal length of treatment, we
decided against utilizing an active-maintenance-treatment
design, as a host of scientific, methodological, clinical,
and financial factors mitigated against such a design [38].
Why not a more tightly controlled randomized control trial design?
A primary goal of this study was to take an initial step
beyond a traditional efficacy study and broaden the pop-
ulation of children and adolescents with OCD that could
benefit from the study. In the spirit of effectiveness
research, the sampling frame was designed to recruit a
broadly representative sample of moderately to severely ill
youth with OCD who are seeking treatment for SRI partial
response, while still including efficacy elements, such as
randomization and carefully specified in/exclusion crite-
ria, which maximize internal validity (see Table 1, Table
2).
Entry criteria
Subject eligibility for study entry was assessed in a step-
wise process, to reduce patient burden and promote effi-
ciency. This step-wise process has been previously
described, but consists of a series of assessment "gates," at
which subject eligibility is evaluated [1]. The primary
entry criteria for the study are subjects who (1) meet DSM-
IV criteria for OCD as their primary diagnosis; (2) have
evidenced a predefined partial response to an adequate
trial of an SRI (as defined below); and (3) still have resid-
ual OCD symptoms severe enough to warrant additional
treatment, as measured by a score 16 or above on the CY-
BOCS (see Table 1).
The choice of a CY-BOCS entry score of 16 was based on
two factors: (1) this represents a threshold entry score
below which subjects would be excluded in most OCD
treatment protocols and (2) an entry CY-BOCS score
below this would leave insufficient room for improve-
ment necessary to detect a treatment effect. Entry criteria
were determined by assessment. Primary OCD diagnosis
was determined from the Anxiety Disorders Interview
Schedule [39]. As previously described, OCD severity was
determined by the CY-BOCS.
Inclusion and exclusion criteria
In the spirit of effectiveness research, the sampling frame
was designed to recruit a broadly representative sample
of youth with OCD seeking augmentation of SRI partial
response, while still including key efficacy elements
(e.g., randomization, specified inclusion criteria) to
ensure internal validity. As described previously, the
effectiveness context of this study implied a framework
in which we would expect some variability across
patients. Our inclusion criteria were purposefully broad
to allow for a group of patients who were indeed ill, but
also highly representative of a large portion of children
and adolescents with OCD who are partial responders to
medication treatment.
Allowable concurrent psychotropic treatment
To increase generalizability beyond the study, concomi-
tant psychotropic medications were allowed as needed
for treatment of common comorbidities (for example,
attention-deficit hyperactivity disorder (ADHD), tics,
other anxiety disorders, and sleep problems) following
cross-site review by the study psychiatrists. To preserve
research integrity, potential subjects taking concomitant
psychotropic medications in addition to their SRI were
reviewed by a cross-site committee before being permit-
ted to enter the study. To provide good clinical care, the
physician treating the patient in the study was aware of
all medications that the patient was being prescribed and
coordinated care with the outside prescriber as needed.
All concurrent medications were assessed prior to
entrance into the study to ensure that the child was on a
stable dose (defined as 4 weeks for ADHD psychostimu-
lants and 12 weeks for other medications) prior to study
entry and that the dose did not change during the acute
study phase.
Allowed concurrent psychosocial treatment
Patients currently receiving supportive psychotherapy,
either in individual or family format, were allowed to con-
tinue as long as the following conditions were met: (1)
The patient was in this treatment for 4 months or more;
(2) The supportive treatment was at a stable frequency not
to exceed once per week; and (3) The treatment did not
include cognitive-behavioral therapy for OCD.
Table 1: Inclusion criteria and rationale
Inclusion Criteria Rationale
Age 7 – 17 inclusive Matches developmental sensitivity of treatments and measures
DSM-IV Diagnosis of OCD Disorder of interest
CY-BOCS total score ≥ 16 Indicates clinically important OCD
Partial responder to optimized SRI trial Target population of interest
Outpatient Inpatient care confounds study treatmentsChild and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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Prior failed trials of CBT
Prior exposure to CBT treatment, per se, was NOT an
exclusion criterion except if the child received an adequate
dose of CBT, which was defined as at least 10 sessions of
CBT that included use of a symptom hierarchy and thera-
pist-assisted exposure/response prevention. Assessment of
an adequate dose of CBT included a review with the child
and parent of the content and homework of previous CBT
for OCD and, when possible, a review with the treatment
provider regarding the techniques included in the previ-
ous treatment. All decisions regarding inclusion or exclu-
sion from the study were made by the cross-site panel.
SRI medication treatment
To ensure maximum generalizability, eligible SRI medica-
tions were determined by expert recommendations and
standard treatment of OCD in the community (see Table
3). Citalopram, escitalopram, fluoxetine, fluvoxamine, par-
oxetine, paroxetine-controlled release, and sertraline were
included as eligible SRI medications both because of their
common use in treatment of OCD in children and research
evidence supporting their efficacy in reducing OCD symp-
toms [15,40-43]. Although not typically first-line medica-
tion treatments of OCD, clomipramine, venlafaxine, and
venlafaxine-extended release are prescribed after a patient
fails a trial of an SRI [21,44-46]. Because this study targeted
partial responders of medication who may have been par-
tial responders to multiple medication trials, these medica-
tions were also included as allowed SRI medications.
Identification of partial responders
To meet the definition of partial response, patients must
have had at least three weeks of stable OCD symptoms at
an SRI dose that is equal to the upper dose (Table 3) OR
Table 2: Exclusion criteria and rationale
Exclusion Criteria Rationale
Other primary or co-primary psychiatric disorder May require additional or different treatments
Suicidal ideation with intent May require additional or different treatments
Pervasive Developmental Disorder(s) (including Asperger's syndrome) May require additional or different treatments
Thought Disorder May require additional or different treatments
Concurrent treatment with psychotropic medication (other than 
stable psychostimulant and/or certain uses of clonidine, tenex, 
trazodone, or neuroleptic) or psychotherapy outside study
Confounds internal validity of treatment assignment
Prior failed trial of adequate dose of CBT for OCD Confounds internal validity of treatment assignment; unsystematic 
sampling bias
PANDAS/maintenance antibiotic for OCD/tics Confounds internal validity of treatment assignment
Mental Retardation Would not permit specified CBT treatment
Pregnancy Potential risk of medication to fetus
Table 3: SRI dosing
Drug Usual Starting dose ~ Mean Dose* Upper Dose Incremental Dose
Citalopram** 20 40 60 20
Clomipramine 50 150 250 50
Escitalopram** 10 20 30 10
Fluoxetine 20 40 60 20
Fluvoxamine 50 175 250 50
Paroxetine 20 30 50 10
Paroxetine-CR 20 30 50 10
Sertraline 50 125 200 50
Venlafaxine** 25 100 225 25
Venlafaxine XR** 37.5 112.5 225 37.5
*Mean dose derived from registration trials, expert recommendation and the applicant's clinical experience
**Not included in Expert Consensus GuidelinesChild and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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patients must have experienced adverse effects as a result
of dosage increase OR patients must have shown a flat
dose-response curve for one dose increment above the
minimum expected starting dose (Table 3). Because most
patients who respond to a SRI do so at a mean dose con-
siderably lower than the maximum, an aggressive forced
titration strategy to raise the dose to the "maximum toler-
ated therapeutic dose" independent of response status was
deemed unwarranted clinically, as it could impose an
undue experimental and adverse event burden on
patients. On the other hand, the possibility of suboptimal
dosing could not be unthinkingly discounted since some
patients do respond when the dose is raised to the maxi-
mum. To balance these imperatives – maximizing benefit
of SRI, minimizing the risk of high dose SRI, and mini-
mizing unnecessary delay in implementing augmenting
treatment, a "within subject" definition of "adequate
dose" that included both dose-response and time-
response considerations was implemented.
Persistent symptoms define partial response
While one standard definition of adequate clinical
response is a 25–30% decline in symptomatology, most
experts agree that the persistence of significant OCD
symptomatology in the face of adequate treatment would
also qualify as an inadequate response to treatment. There
are three reasons we defined partial response on the basis
of persistent OCD, rather than by a pre-defined CY-BOCS
symptom reduction:
First, many psychiatric patients may receive their initial
treatment in primary care, and then be referred for psychi-
atric consultation. In these cases, obtaining a CY-BOCS
change score would not be feasible, making this standard
unobtainable.
Second, based on the mean doses in industry funded trials
(each of which used forced upward titration schedules)
and the POTS I study, after 12 weeks of adequate treat-
ment, full remission is unlikely with a higher SRI dose or
longer treatment duration even if such increases were pos-
sible, which is typically not the case.
Third, upward titration is often limited by adverse events,
which may or may not be persistent.
To establish partial response, a POTS II pharmacothera-
pist considered the following (see Figure 1): 1) Adequate
trial at or above the minimum starting dose; 2) Maximum
dose; 3) Intolerable side effects at a dose above his or her
current dose; 4) Stable current dose for 3 weeks; 5) Mini-
mum of 9 weeks of treatment.
If the patient had been treated with an SRI for at least nine
weeks AND had been at a stable dose for the past three
weeks, e.g., the dose response curve was flat indicating no
further improvement in OCD symptoms, OR the patient
did not tolerate a dose increase to the next higher dose OR
the patient had been at the maximum allowable dose for
three weeks, then the patient was eligible for randomiza-
tion to one of the three POTS II treatment conditions.
Patients not meeting this definition when presenting ini-
tially for study participation were allowed to return for
reevaluation by the study team when sufficient dose and
duration criteria had been met to be considered for study
entry. At that point, if eligible, the patient was promoted
to randomization.
Waiver of optimization
Patients who had specific circumstances that precluded
the use of the above medication optimization paradigm
were able to receive review by a cross-site committee of
study psychiatrists to determine whether they should be
considered effectively optimized. This included situations
in which the patient had adverse events on another SRI
medication and/or parent or psychiatrist reluctance or
refusal to raise the SRI dose. Waivers were documented
and coded for later consideration in data analysis.
Flow chart for partial response Figure 1
Flow chart for partial response.
Starting SSRI
Dose Adequate?
Optimize No
Yes
One or More Dose
Increments Above
Starting Dose for 3
Weeks?
Optimize No
Increase
Attempted but
AE Limited
Nine or More
Weeks of
Treatment?
Yes
Yes
EITHER no improvement in
OCD symptoms after last
dosage increase OR at
maximum allowable dose
Yes
Yes
Optimize No
Optimize No
Eligible
No
No
IneligibleChild and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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Food and Drug Administration (FDA) advisories recom-
mend that health care providers carefully monitor
patients receiving antidepressants for possible worsening
of depression or suicidality, especially at the beginning of
therapy or when the dose either increases or decreases.
Subsequent to the FDA's issuance of the "black box" warn-
ing for SRI medication, concern of adverse effects at
increasingly higher doses of medication increased among
parents, pediatricians, psychiatrists, and study personnel.
Thus, patients who had not achieved optimization criteria
(e.g., they had not experienced a flat dose-response curve
at a moderate to low level of medication), but whose par-
ents or provider declined further increases to the medica-
tion were allowed study entry via the previously described
waiver process.
Assessment
The primary instrument for assessing OCD was the CY-
BOCS, which assesses obsessions and compulsions sepa-
rately on time consumed, distress, interference, degree of
resistance, and control [47,48]. We used the CY-BOCS
symptom checklist and severity scale to inventory past
and present OCD symptoms, initial severity, total OCD
severity, relative preponderance of obsessions and com-
pulsions, and degree of insight [29]. The CY-BOCS is a cli-
nician-rated instrument that involves merging data from
clinical observation and parent and child report; inde-
pendent evaluator (IE) reliability training is described
below.
Several procedures were set in place to maintain the rater's
blind to patient treatment status. The IEs at all sites were
doctoral level psychologists with specific training in the
assessment of pediatric OCD. Notably, the IEs at each site
were not actively involved in research program beyond
their role as IE, thus further promoting their independ-
ence. They did not attend weekly study coordination or
treatment supervision meetings or weekly cross-site calls,
however, there was a monthly cross-site phone meeting
for the IEs only led by the IE coordinator from the Duke
site. IEs rated patients on the day of treatment, but in a dif-
ferent physical location to ensure rater blinding to treat-
ment status. Patients were instructed not to disclose
treatment status to their IE; the IE was also instructed not
to inquire about treatment status. To assess the adequacy
of the IE blinding procedure, IE were asked to guess
assignment to condition (MM+CBT, MM+I-CBT, or MM)
at the end of the treatment.
Improvement and severity ratings were obtained from the
therapist (MM+CBT) and psychiatrist (MM+ and MM+I-
CBT groups) at every 4th treatment visit. All self- and par-
ent-report measures were completed on scheduled visit
days. In the event that a patient/parent was unable to read
the self-report measures, personnel unconnected with the
study provided assistance. Because all study participants
received active SRI treatment, clinical assessment of side
effects using the child, parent, and clinician versions of
side effects and suicidal and homical ideation was com-
pleted by the physician for all subjects in the study irre-
spective of treatment assignment. The pharmacotherapist
assessed side effects and possible risk factors associated
with SRIs; thereby tracking adverse occurrences between
study visits, the severity, possible causes and outcome.
Additional measures were included in the study to address
secondary aims and questions of predictors of treatment
response (see Table 4).
Three treatment conditions
MM
Once randomized, all patients were assigned to a child/
adolescent psychiatrist from whom they received mainte-
nance SRI medications (MM) for the duration of the
study. MM visits were conducted on a maintenance visit
schedule at weeks 1, 2, 4, 6, 8, 10, and 12. In accordance
with sound clinical practice, in addition to monitoring
clinical status and medication effects, pharmacotherapists
offered general encouragement to resist OCD and told
patients that medication will make this easier. In distinc-
tion to the pharmacotherapist in the MM+I-CBT assign-
ment who implemented a systematic EX/RP protocol, the
pharmacotherapist in MM alone and MM+CBT imple-
mented no systematic or unsystematic cognitive therapy
(CT) or EX/RP program. Insight-oriented or interpersonal
psychotherapy, other CBT interventions, or family ther-
apy provided by the study psychiatrist were similarly pro-
scribed during the 12-week study period.
I-CBT
MM+I-CBT is a protocol in which the psychiatrist who
manages medication also provides instructions in the CBT
procedures that have been found to help reduce OCD
symptoms, namely EX/RP. MM+I-CBT was constructed as
a single-doctor "best practice" treatment with three pri-
mary goals in mind: (1) inclusion of the main psychoed-
ucational and EX/RP components of the full CBT
protocol; (2) feasibility of training psychiatrists to per-
form the CBT component of MM+I-CBT; (3) integration
with protocol medication management visits; and (4) fea-
sibility of implementation with the constraints of a busy
practice oriented primarily toward pharmacotherapy. As
shown in Table 5, MM in MM+I-CBT were administered
according to the MM protocol (7 visits over 12 weeks),
with additional time for I-CBT provided via: (1) increas-
ing the time available for I-CBT by increasing visit length;
and (2) by emphasizing I-CBT at each session, which was
permissible and practical because the time demands of
maintenance pharmacotherapy are minimal relative to
acute titration visits. Fewer or shorter sessions would have
vitiated the "best practice" philosophy of MM+I-CBT;
given that we hypothesized an intermediate response rate
for MM+I-CBT, more or longer sessions would have viti-Child and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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ated the comparison to MM+CBT and would be unfeasi-
ble in clinical practice.
MM+I-CBT does not include the following components
that are part of the full CBT protocol: (1) Cognitive Train-
ing (CT) except for bossing back metaphors, and external-
izing techniques, such as using a "nickname" for OCD;
(2) the fear thermometer as an aid to creating and re-eval-
uating the stimulus hierarchy; (3) detailed hierarchies
addressing different aspects of OCD; (4) imaginal expo-
sure instructions; (5) therapist-assisted EX/RP in the
office; (6) dyadic parent sessions except as noted; (7)
detailed instructions regarding pitfalls in CBT and meth-
ods for moving stalled treatment forward. Exclusion of
these components, while not detracting from the core
components of CBT, was necessitated by both the time
and the expertise required for their implementation [49].
CBT
As Table 6 shows, the CBT protocol to be administered by
the study psychologist in the context of MM+CBT consists
Table 4: Measures By domain, variable type and rater
MEASURE Domain Who Gates Baseline Acute Treatment Naturalistic Follow-up
Phone screen In/Exclusion SC X
Demographics, history Caseness SC X
Treatment history Caseness T X
ADIS Caseness/Comorbidity T X
Yale Global Tic Scale Tic disorders T X
PANDAS interview PANDAS T X
CY-BOCS OCD T, IE X X (IE) X X
NIMH Global (Impairment) OCD T, IE X X (IE) X X
Clinical Global (CGI-I and CGI-S) OCD severity T, IE X X X X
COIS Functional impairment C, P X X X
Expectancy Ratings – Medication "Non-specific" effects C, P, T X X X
Expectancy Ratings – Psychotherapy "Non-specific" effects C, P, T X X X
Consumer satisfaction Consumer satisfaction C, P X X X
IE Blindness IE Blind IE X X
MASC Child anxiety C X X X
CDI Child depression C X X X
Conners Parent Rating Scale Disruptive behaviors P X X X
BSI Parent psychopathology P X X X
Family Assessment Measure Family functioning P X X X
PQ-LES-Q Quality of life P X X X
CGAS Quality of Life T X X X
HARM form Adverse Events: Suicidal and homicidal 
ideation and behavior
TX XX X
Pediatric Adverse Events Rating 
Scale (PAERS)
Adverse Events C, P, T X X X X
Teasing Questionnaire (TQ) Social Functioning C X
SEQ-S Social Functioning C X
Attitudes Toward My Child Family Functioning P X
Parent Reaction Questionnaire Family Functioning P X
WAM Child Emotionality C X
SC = study coordinator; T = clinician rated, C = child self-report, IE = independent evaluator rated, P = Parent rated self-report
Table 5: I-CBT treatment protocol
Wk/Visit Number Time (Min) Goals
Week 1/Visit 1 90 Psychoeducation
Week 2/Visit 2 50 Mapping OCD, EX/RP
Week 3-phone 10–15 Ckeck-in for exposure
Weeks 4, 6, 8/Visits 3, 4, & 5 30 EX/RP
Week 5-phone 10–15 Check-in for exposure
Week 10/Visit 6 30 EX/RP
Relapse prevention
Week 12/Visit 7 30 End of treatmentChild and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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of 14 visits over 12 weeks involving: (1) psychoeducation,
(2), CT, (3) mapping OCD, and (4) EX/RP. The CBT Treat-
ment Manual used in the study is adapted from March
and Mulle [50] and was used in a previous collaborative
study of treatments for pediatric OCD [2]. Except for
weeks 1 and 2, when patients came twice weekly, all visits
were administered on a once/week basis, last one hour,
and also include one between-visit 10 minute telephone
contact scheduled for weeks 3–12. Psychoeducation,
defining OCD as the identified problem, cognitive train-
ing, and development of a stimulus hierarchy (mapping
OCD) took place during visits 1–4; EX/RP comprised vis-
its 5–12, with the last two sessions incorporating general-
ization training and relapse prevention. Each session
included a statement of goals; review of the previous
week; provision of new information; therapist-assisted
practice; homework for the coming week; and monitoring
procedures. Consistent with sound clinical practice and
by virtue of the study design, the psychiatrist and psychol-
ogist were aware that the child assigned to MM+CBT was
seeing another treatment provider, and conferred regu-
larly as to the clinical progress made by the child. How-
ever, there were no treatment dependencies, e.g. the dose
of medication did not vary as a function of progress in
CBT.
All study CBT therapists underwent in-person group and
individual training (with study PIs) that included famil-
iarization with the treatment manuals, followed by exten-
sive role-playing of treatment procedures as well as
videotaping. To maintain treatment fidelity throughout
the study, all sessions were videotaped, all therapists
received ongoing, weekly case supervision, and 15% of all
CBT tapes were selected at random for review by the CBT
supervisor. Supervision consisted of a weekly cross-site
conference call in which all actives cases were discussed,
review of videotapes of therapy sessions, and feedback to
therapists based on tape review. To establish treatment
fidelity, two evaluators, trained until they reached at least
80% agreement, reviewed 20% of MM+CBT and 20% of
MM+I-CBT tapes randomly selected, ensuring equal repre-
sentation of each session to ensure that intervention pro-
cedures were followed and that no proscribed treatment
techniques are being used. Reliability was calculated
between the two evaluators as well as between each eval-
uator and the study therapist. Eighty percent agreement
was considered acceptable.
In both the CBT and I-CBT protocols, individualization
and developmental appropriateness of treatment was pro-
moted by allowing flexibility within the constraints of
fixed session goals. More specifically, therapists adjusted
the level of discourse to the specific interests, level of cog-
nitive functioning, social maturity and capacity for sus-
tained attention of each patient. For example, younger
patients required more redirection and activities in order
to sustain attention and motivation. Adolescents were
more sensitive to the effects of OCD on peer interactions,
which in turn required more discussion. In addition, cog-
nitive interventions required adjustment to the develop-
mental level of the patient, with adolescents, for example,
less likely to appreciate giving OCD a "nasty nickname"
than younger children. Developmentally appropriate
metaphors relevant to the child's areas of interest and
knowledge were also used to promote active involvement
in the treatment process. For instance, an adolescent male
football player treated with CBT was better able to grasp
treatment concepts by casting them in terms of offensive
and defensive strategies employed during football games
(e.g., handling blitz assignments on the offensive line).
Patients whose OCD symptoms entangled family mem-
bers required more attention to family involvement in
treatment planning and implementation than those with-
out as much family involvement. Nonetheless, the general
format and goals of the treatment sessions were the same
for all children.
End of treatment recommendations
With the exception of subjects who withdrew consent for
treatment and assessment (drop outs) for whom we could
not provide recommendations, as the treatment relation-
ship was severed by the patient, ethical principles require
that all participants be given recommendations for any
indicated further treatment and appropriate referrals at
the end acute of acute treatment.
Patients who completed MM only, were offered the full
course of CBT at no cost from the study team or, if they
Table 6: CBT treatment protocol
Wk/Visit Number Time (min) Goals
Week 1/visits 1 & 2 120 (2 visits) Psychoeducation
Cognitive training
Week 2/Visits 3 & 4 120 (2 visits) Mapping OCD
Cognitive training
Week 3–12/Visits 5–14 60 (1 visit/week) Exposure and response prevention
Visits 11–12 60 (1 visit/week) Relapse prevention
Visits 1,7 & 11 Included in above-described session time Parent sessionsChild and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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preferred, were offered community referral(s). The cost of
medication management and SRI medication was not
provided in the open treatment. MM excellent responders
(CY-BOCS  ≤ 10) who did not choose open CBT were
offered open CBT treatment (at no cost) if they relapsed
within six months of ending acute treatment. Based on
evaluation of clinical response using a clinician assigned
CY-BOCS, excellent responders (CY-BOCS ≤ 10) to
MM+CBT and MM+I-CBT received end-of-treatment rec-
ommendations based on their clinical status.
MM+I-CBT non-responders or partial responders (CY-
BOCS > 10) were offered the full CBT protocol at no cost
from the study team or, if they prefer, are offered commu-
nity referral. The cost of medication management and SRI
medication was not provided in open CBT treatment.
MM+CBT non-responders were referred to community care
with specific end-of-treatment recommendations.
Referrals to treatment in the community were made from
a standard referral list of providers with expertise in the
care of pediatric OCD. To minimize site differences, the
process was standardized across the three sites by using a
debriefing script. Briefly, this script a) provided the family
a chance to state any concerns or questions they had; b)
provided a summary of progress, using clinical indicators;
c) outlined the possible available treatment strategies,
emphasizing those in the assigned treatment arm but also
explaining the others; and d) made recommendations
about appropriate continued treatment.
Adjunctive Services and Attrition Prevention (ASAP)
In a long-term trial, ethical and practical obligations
require a mechanism for providing services to children
and families that are not easily accounted for within the
framework of protocol treatments [51,52]. For example,
an investigator may find it necessary to address a signifi-
cant decline in functioning (as opposed to a lack of
improvement), as in the case of a severe adverse reaction
to medication or dangerousness to self or others. Regard-
less of the child's assigned treatment condition, children/
families who experienced clinical worsening were pro-
vided within protocol adjunctive services as follows: two
Adjunctive Services and Attrition Prevention (ASAP) ses-
sions were available during acute treatment to provide
supportive evaluation services to determine whether the
child may remain in the study or other treatment was
needed. ASAP sessions were used to prevent premature
termination (investigator initiated protocol violation)
and dropping out (withdrawal of consent). Sessions were
provided by the child's study treatment provider (psychi-
atrist for MM and MM+I-CBT, psychologist for MM+CBT),
and may have been carried out with the child's family. All
ASAP procedures were reviewed/approved and docu-
mented by a cross-site ASAP panel. ASAP procedures,
which provide for optimal sample maintenance and for
ethical treatment, have been used successfully in previous
multi-site trials [2,51,52]. From a data analytic stand-
point, premature termination will be handled via the use
of random regression (RR) models which permit estima-
tion of changes in continuous repeated measures on both
a population and subject-specific level, without necessi-
tating last observation carried forward (LOCF) or exclu-
sion of subjects with missing data in the dependent
variable.
Sample size and randomization
The total "n" and the group sample sizes were driven by
power requirements. Using a conventional definition of
responder as those who achieve at least a 30% reduction
on the CY-BOCS; we estimated response rates of 70%,
40%, and 10% for MM+CBT, MM+I-CBT, and MM,
respectively. The 30% difference in response rates is
defined as a difference in the probability of normalization
(CY-BOCS less than or = to 10, not a change score of 30%)
as the threshold of clinically meaningful difference for
purposes of power calculations. Based on data from POTS
I, we estimated a modest response for MM alone (10%)
and added 30% to that to come up with an expected 40%
response rate for ICBT and added another 30% to come
up with the response rate for CBT.
Accordingly, a two group X2 test with a 0.050 two-sided
significance level would have 80% power to detect the dif-
ference between a Group 1 proportion of 0.600 and a
Group 2 proportion of 0.300 (odds ratio of 0.286) when
the sample size in each group was 42 and the total sample
size was approximately 130. To allow for 15% drop outs
in intent-to-treat analyses in which all subjects' data are
included, we elected a sample size of 150, and expect to
complete the trial at a total "n" of approximately 140 sub-
jects. The expected drop out rates were based on data from
POTS I in which only 15 of 112 patients (13%) dropped
out [2]. Given that we will be using more powerful mixed
effect regression models for scalar outcomes and general-
ized estimating equations for categorical outcomes, power
should be sufficient to detect a clinically meaningful effect
if one is present.
Using a list created prior to study initiation, randomiza-
tion was done at the subject level at each site. The actual
procedure, which was monitored by the Data Center at
Duke, was a stratified randomization on site alone, with
randomized permuted blocking (on age, gender, and
severity of clinical presentation) within each stratum [53].
Subjects were considered randomized when they learned
of their assignment to condition after the baseline assess-
ment. Subjects who dropped out prior to randomization
will not be included in data analyses.Child and Adolescent Psychiatry and Mental Health 2009, 3:4 http://www.capmh.com/content/3/1/4
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Data management and analysis
Our overall data analytic strategy has been designed to
meet the objectives outlined in our specific aims. Accord-
ingly, the data analysis plan consists of: (1) data inspec-
tion, (2) descriptive analyses, (3) hypothesis testing, and
(4) model specification. Following completion of data
collection, analyses will proceed in two steps using a
mixed effect "random regression" (RR) model. RR permit
modeling of outcomes at the individual level using both
individual and cluster level variables while adjusting for
the intraclass correlation present in the data [54]. The
models do not make assumptions requiring equal sample
sizes, and thus covariates, either time varying or time-sta-
tionary, can be included. RR also permits estimation of
changes in continuous repeated measures on both a pop-
ulation and subject-specific level, without necessitating
last observation carried forward (LOCF) or exclusion of
subjects with missing data in the dependent variable.
Thus, RR provides an efficient and typically more power-
ful means of assessing time-invariant characteristics (e.g.,
gender) and time-dependent variables (e.g., treatment
dose) on mean changes in the dependent variable [55].
In step one, as recommended by Lavori et al. [56], initial
analyses will be conducted under an "intent-to-treat"
model in which all assessment points at all visits will be
obtained and data analyzed according to treatment
assignments at randomization. In step two, we will con-
duct "completer analyses" on those children completing a
full course of treatment. Once past intent-to-treat (ITT)
main outcome analyses as advocated by clinical trials
experts [53,56], subsequent analyses will focus on predic-
tors of outcome [57,58]. We have sufficient power to
detect moderate to large treatment-covariate interactions,
but did not stratify on the basis of moderator variables
and because the study was not "powered" to include
detection of moderator or mediator effects, these analyses
are considered secondary to the overall ITT analyses [59].
Numbers needed to treat (NNT) will be used to analyze
group differences in remission rates [60]. The NNT repre-
sents the number of patients who would need to be
treated with CBT to produce one additional responder
(i.e., CY-BOCS reduction 30%) beyond that obtainable
with I-CBT. Lower NNT scores are better, with most effec-
tive therapies for psychiatric disorders showing NNT indi-
ces of 3 to 6. Treatment response will be defined in two
ways: 1) the primary continuous outcome measure is the
IE-rated CY-BOCS and 2) the primary categorical outcome
measure is excellent response on the IE CY-BOCS (≤ 10).
Given the intensive fidelity/reliability checks built into
the protocol, site differences that move in the same direc-
tion – i.e., that differ in quantity or magnitude but not
quality or direction of effect – will be seen as contributing
to the generalizability of the findings. While Lavori and
others have noted that site differences need not be
accounted for statistically unless divergent by treatment
and clinically meaningful [53,56], site will be accounted
for as a fixed effect variable in all analyses.
Conclusion – potential implications of study
To date, no controlled studies have evaluated the efficacy
of any augmentation treatment in pediatric OCD, which
leaves the field without an adequate scientific foundation
to guide the management of partial response. Finding
expertise in CBT for OCD in community settings has
proven difficult, and thus it is imperative to determine
whether CBT can be effectively disseminated to the men-
tal health providers who most often encounter OCD in
their clinical practice, namely child psychiatrists and pri-
mary care physicians.
One potential weakness of the study is the cross-cultural rel-
evance of the results. Partial response to SRI medication may
be a clinical problem that occurs more frequently in the
United States, given overall lower rates of psychopharmaco-
logical treatment of pediatric patients outside the United
States [61,62]. While the problem of partial response is nec-
essarily less relevant in a culture in which medication is pre-
scribed less frequently, the phenomena remains and this
study will provide a better understanding of it.
This study begins to address the effectiveness of CBT using
real-world patients, who have had some response to med-
ication but continue to experience clinical levels of OCD
symptoms. It compares standard EX/RP for OCD with a
briefer, instructional CBT model. As such, the results of
this study can provide directions for dissemination of CBT
models, suggesting what adaptations should be made to
treatment to increase feasibility in real-world settings. In
addition, the study may answer initial questions regarding
which patients need what treatment, providing empirical
support for a stages of care treatment model.
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